Analyst Ratings for Silver Standard Resources Inc. (SSRI)

Updated: 2017-07-27

Silver Standard Resources Inc. (NASDAQ:SSRI) was awarded an average rating of Overweight from investment analysts following the stock. About 30 days ago, SSRI was issued an average rating of Overweight.

Of the 10 analysts covering the stock, 5 gave it a buy rating, 1 issued an overweight rating, 4 issued a hold rating, 0 issued an underweight rating, and 0 issued a sell rating. Over the past 90 days, the number of analysts that are bullish on the stock has increased by 1. During this time, the number of analysts bearish on the stock has increased by 0.

Several price targets were given for SSRI by the analysts covering the stock. The maximum price target given was 17.26, which equates to a potential upside of 80.53 percent. The minimum price target given was 10.56, implying a possible loss of 10.45 percent. Note that investment analysts can be biased in their reporting on companies's ratings and price targets.

Analysts have revised their earnings estimates downwards for this quarter, by about -0.89 percent on average, compared to last month. The average change in earnings estimates over the last 90 days is 0 percent. Meanwhile, fiscal year estimates have been revised downwards by -12.57 percent, compared to last month. If we look at the last 90 days instead, we find a net average change of 0 percent in FY estimates.

Another thing investors often look at is the level of agreement among analysts' revisions. Over the past month, 0 analysts increased their quarterly estimates, which can be compared to the 2 analysts that decreased their estimates. Over the same time period, 0 analysts revised their FY earnings estimates upwards, compared to 2 analysts that revised their FY estimates downwards.

The growth rate of SSRI's earnings is estimated by analysts to be -53.99 percent. Another measure frequently examined by investors is the PEG ratio. A lower PEG ratio is favorable, because that is often interpreted as the company being fairly priced relative to its growth rate. Wall Street investors typically prefer a PEG ratio to be smaller than 1, though it could be better to see where the ratio stands relative to peers in the industry. SSRI has a PEG ratio of -0.27.

In the last 52-weeks, SSRI has achieved a high of 15.84 and a low of 7.70. Currently the stock is 24.17 percent higher than its low, and below the high by 39.64 percent. SSRI has a price/earnings ratio of 14.59. Investors typically compare the P/E ratio to a company's peers in the industry. The SSRI value stock report compares SSRI to some of its peers using value stock charts. The stock has a market capitalization of $1.17 billion. SSRI is estimated to release their earnings results for the quarter on 0000-00-00, days from today.